FLNA Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
FLNA is not a good buy right now for a beginner long-term investor with $50,000-$100,000 to deploy. The stock is in a weak pre-market down move, technicals are bearish, there is no strong proprietary buy signal, and the latest news points to clinical/regulatory pressure. Based on the available data, I would avoid buying it now and favor a sell/avoid stance.
The current trend is bearish. FLNA is trading pre-market at 1.30, down 4.41%, and below the pivot level of 1.495. MACD histogram is negative at -0.0209, confirming downside momentum, even if the contraction suggests the move is slowing. RSI_6 at 28.933 is near oversold territory but not yet a clear reversal signal. The moving average structure is bearish with SMA_200 > SMA_20 > SMA_5, which indicates the long-term trend remains weak. Key support is near 1.371 and 1.294, while resistance sits at 1.619 and 1.696. Overall, the chart does not show a healthy long-term entry point.
Latest quarter reported is 2025/Q4. Revenue was 0, unchanged year over year, so there is no visible sales growth yet. Net income worsened to -12.539 million, down 54.56% YoY, and EPS fell to -0.26, down 54.39% YoY. Gross margin is still 0, which confirms the company is not yet generating operating traction. For a long-term beginner investor, the latest financials do not support a buy thesis.
No direct analyst rating or price target change data was provided. Based on the available Wall Street-style inputs, the pros are the low cash burn concerns being partly offset by the reported cash reserve and no debt, plus speculative call-heavy options sentiment. The cons are more important: clinical hold/FDA scrutiny, a 52-week low, weak technical trend, and deteriorating earnings. Overall, the Wall Street view appears cautious to negative.
